Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Accounts Payables (2019 - 2025)

Bioadaptives' Accounts Payables history spans 7 years, with the latest figure at $232725.0 for Q4 2025.

  • Quarterly results put Accounts Payables at $232725.0 for Q4 2025, up 29.68% from a year ago — trailing twelve months through Dec 2025 was $232725.0 (up 29.68% YoY), and the annual figure for FY2025 was $232725.0, up 29.68%.
  • Accounts Payables for Q4 2025 was $232725.0 at Bioadaptives, up from $230768.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $473501.0 in Q3 2024 to a low of $57258.0 in Q1 2021.
  • The 5-year median for Accounts Payables is $358160.0 (2022), against an average of $312007.2.
  • The sharpest move saw Accounts Payables skyrocketed 467.47% in 2022, then tumbled 59.54% in 2024.
  • Year by year, Accounts Payables stood at $247750.0 in 2021, then surged by 65.46% to $409920.0 in 2022, then rose by 8.21% to $443579.0 in 2023, then tumbled by 59.54% to $179458.0 in 2024, then increased by 29.68% to $232725.0 in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $232725.0, $230768.0, and $204081.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.